Shenfu Injection: Preserving Glycocalyx Integrity to Combat Sepsis Mortality

Sepsis remains a critical concern for medical practitioners worldwide due to its high mortality rates and complex pathophysiology. Furthermore, recent investigations into Shenfu Injection sepsis treatment reveal its capacity to protect the vascular glycocalyx and inhibit caspase-11-mediated inflammatory pathways. This botanical formulation, derived from traditional medicine, offers a multi-target approach that addresses both endothelial stability and cellular integrity during severe infections.

Mechanism of Shenfu Injection Sepsis Treatment

Specifically, the treatment blocks the interaction between intracellular lipopolysaccharides (LPS) and murine caspase-11. Consequently, this inhibition prevents the cleavage of gasdermin D, which effectively halts pyroptosis—a form of programmed inflammatory cell death. Moreover, SFI inhibits heparanase activity, an enzyme that typically degrades the glycocalyx lining of blood vessels. Therefore, the protection of this barrier significantly reduces vascular leakage and systemic organ damage.

Researchers utilized murine models to demonstrate that SFI improves survival rates significantly. In endotoxemia tests, the seven-day survival rate rose from 15% to 54% following treatment. Additionally, the injection markedly decreased plasma levels of pro-inflammatory cytokines and markers of lung and liver injury. As a result, the structural preservation of the endothelial glycocalyx appears central to the drug's therapeutic efficacy in preventing septic lethality.

Clinical Implications for Intensive Care

While the study primarily focuses on animal models, the implications for human critical care are noteworthy. In India, where sepsis contributes heavily to hospital mortality, understanding the molecular mechanisms of SFI provides a foundation for integrated therapeutic strategies. Because the formulation stabilizes microcirculation and suppresses lethal cytokine storms, it may serve as a valuable adjunct alongside standard sepsis protocols. Future clinical trials should further validate these findings to refine emergency management guidelines.

Frequently Asked Questions

What is Shenfu Injection?

Shenfu Injection (SFI) is a standardized botanical formulation extracted from Red Ginseng and Aconite. It is widely used in some clinical settings to treat shock, heart failure, and severe inflammatory conditions like sepsis.

How does SFI improve survival in sepsis?

SFI improves survival by inhibiting caspase-11-dependent pyroptosis and preventing the degradation of the vascular glycocalyx, which helps maintain organ function and reduces systemic inflammation.

Disclaimer: This content is for informational and educational purposes only. It does not constitute medical advice or substitute for professional consultation. Refer to the latest local and national guidelines for clinical practice.

References

Zhang C et al. Shenfu Injection reduces septic lethality by preserving glycocalyx integrity and inhibiting caspase-11-dependent pyroptosis. Inflamm Res. 2026 Apr 01. doi: undefined. PMID: 41917468.

Li Y, et al. Shenfu injection for sepsis and septic shock: a systematic review and meta-analysis. Evid Based Complement Alternat Med. 2020;2020:1-12. doi: 10.1155/2020/2324709.

Zhang L, et al. Integrated Clinical and Network Pharmacology Study Reveals the Efficacy and Multi-Target Mechanism of Shenfu Injection in Septic Shock. medRxiv. 2026. doi: 10.64898/2026.03.20.26348945.